Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age

NCT00970307 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

421

Enrollment

INDUSTRY

Sponsor class

Conditions

Tetanus
Diphtheria
Haemophilus Influenzae Type b
Poliomyelitis
Acellular Pertussis
Hepatitis B
Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

Interventions

BIOLOGICAL: GSK2202083A vaccine
BIOLOGICAL: 10-valent pneumococcal vaccine (GSK 1024850A)
BIOLOGICAL: Infanrix hexa™
BIOLOGICAL: Menjugate®

Sponsor

GlaxoSmithKline